

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

761359Orig1s000

Trade Name: Entyvio injection and Entyvio Pen injection

Generic or Proper Name: vedolizumab

Sponsor: Takeda Pharmaceuticals USA

Approval Date: April 18, 2024

Indication: ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of:

- moderately to severely active ulcerative colitis (UC).
- moderately to severely active Crohn's disease (CD).

CENTER FOR DRUG EVALUATION AND RESEARCH

761359Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) • Summary Review • Clinical • Non-Clinical • Statistical • Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761359Orig1s000

APPROVAL LETTER



BLA 761359
BLA 125476/S-060 and S-061
BLA 761133/S-005 and S-006

**BLA APPROVAL
SUPPLEMENT APPROVALS**

Takeda Pharmaceuticals U.S.A., Inc.
Attention: Yu-Chi Chu, RAC (US)
Sr. Manager, Global Regulatory Affairs – GI²
125 Binney Street
Cambridge, MA 02142

Dear Yu-Chi Chu:

Please refer to your biologics license application (BLA) (BLA 761359) dated and received June 30, 2023, and your amendments, submitted under section 351(a) of the Public Health Service Act for Entyvio (vedolizumab) injection, for subcutaneous use and Entyvio Pen (vedolizumab) injection, for subcutaneous use. This application provides for the treatment of adults with moderately to severely active Crohn's disease.

Also refer to your supplemental biologics license applications (sBLA) (BLA 125476/S-060, BLA 761133/S-005), dated and received March 29, 2024, submitted under section 351(a) of the Public Health Service Act for Entyvio (vedolizumab) injection and Entyvio Pen (vedolizumab) injection, for subcutaneous use. These Changes Being Effected (CBE-0) supplements provide a response to the safety related labeling updates requested by the Division of Gastroenterology, incorporating inclusion of the terms, "interstitial lung disease, pneumonitis" into the *Postmarketing Experience* subsection of the Prescribing Information.

Lastly, refer to your sBLAs (BLA 125476/S-061, BLA 761133/S-006) dated and received March 29, 2024, for Entyvio (vedolizumab) for injection and Entyvio (vedolizumab) injection, for subcutaneous use, and Entyvio Pen (vedolizumab) injection, for subcutaneous use. These Prior Approval supplemental biologics applications provide for alignment of the Prescribing Information, Medication Guide, and Instructions for Use incorporating the addition of Entyvio (vedolizumab) injection, for subcutaneous use, and Entyvio Pen (vedolizumab) injection, for subcutaneous use, for the treatment of adults with moderately to severely active Crohn's disease.

LICENSING

We have approved your BLA for Entyvio (vedolizumab) injection and Entyvio Pen (vedolizumab) injection effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Entyvio (vedolizumab) injection and Entyvio Pen (vedolizumab) injection under your existing Department of Health and

Human Services U.S. License No. 1898. Entyvio (vedolizumab) injection and Entyvio Pen (vedolizumab) injection are indicated for treatment of adults with moderately to severely active Crohn's disease.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture subcutaneous vedolizumab drug substance at (b) (4)

The final formulated prefilled syringe (PFS) drug product will be manufactured, filled, and packaged at (b) (4). The device will be assembled, labeled, and packaged at Takeda Austria GmbH, Linz, Austria (FEI: 3001157285). You may label your product with the proprietary name, Entyvio, and market it in a single-dose PFS with needle safety device (108 mg/0.68 mL); you may label your product with the proprietary name, Entyvio Pen, and market it in a single-dose prefilled pen (108 mg/0.68 mL).

DATING PERIOD

The dating period for Entyvio and Entyvio Pen shall be 18 months from the date of manufacture when stored at $5^{\circ}\text{C} \pm 3^{\circ}\text{C}$, protected from light. The date of manufacture shall be defined as the date of final sterile filtration of the formulated PFS drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) $^{\circ}\text{C}$.

We have approved the stability protocol in your license application for the purpose of extending the expiration dating period of your drug product under 21 CFR 601.12.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Entyvio and Entyvio Pen to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Entyvio and Entyvio Pen, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling:

- Addition of page numbers to the first and second page of the Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on November 7, 2023, and March 1, 2024, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically to BLA 761133 according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761359.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for vedolizumab was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues that were unexpected for a biologic of this class or in the intended population.

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages birth to <2 years because necessary studies are impossible or highly impracticable. This is because the incidence of ulcerative colitis in children ages birth to <2 years of age is very low.

We are deferring submission of your pediatric studies for ages ≥ 2 to <18 years of age for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act are required postmarketing studies. The pediatric studies previously issued at the time of initial approval of BLA 761133 (4493-2 and 4493-3) will address the required pediatric assessments for this application. As such, no additional postmarketing required studies are being issued with this approval. The status of these postmarketing studies must be reported annually according to 21 CFR 601.28 and section 505B(a)(4)(B) of the Federal Food, Drug, and Cosmetic Act. As this BLA is being administratively closed, submit the protocol(s) to your IND 118980, with a cross-reference letter to BLA 761133.

Reports of these required pediatric postmarketing studies must be submitted as a BLA or as a supplement to your approved BLA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.
U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at <https://www.fda.gov/combination->

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

[products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products](#).

We have now administratively closed this BLA. Therefore, carton and container final printed labeling (if requested above), all 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, promotional materials and other submissions should be addressed to the parent **BLA 761133** for this product, not to this BLA. **In the future, do not make submissions to BLA 761359.**

If you have any questions, contact Kelly Richards, Senior Regulatory Health Project Manager, at (240) 402-4276 or email at kelly.richards@fda.hhs.gov

Sincerely,

{See appended electronic signature page}

Tara A. Altepeter, M.D.
Associate Director for Therapeutic Review
Division of Gastroenterology
Office of Immunology and Inflammation
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TARA A ALTEPETER
04/18/2024 03:07:38 PM